Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators—a review
International Journal of Immunopathology and Pharmacology · 2023
DOI: 10.1177/03946320231178769 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Alexandra-Ligia Dinca und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania. Hauptthemen laut MEDLINE: Inflammation Mediators, Ovarian Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
At the level of the genital system, ovarian neoplasm is the most frequent cause of morbidity and mortality. In the specialized literature, the coexistence of an inflammatory process is admitted from the early stages of the evolution of this pathology. Starting from the importance of this process, both in determinism and in the evolution of carcinogenesis and summarizing the field of knowledge, for this study we considered two objectives: the first was the presentation of the pathogenic mechanism, through which chronic +ovarian inflammation is involved in the process of carcinogenesis, and the second is the justification of the clinical utility of the three parameters, accepted as biomarkers of systemic inflammation: neutrophil-lymphocyte ratio, platelet lymphocyte ratio, and lymphocyte-monocyte ratio in the assessment of prognosis. The study highlights the acceptance of these hematological parameters, with practical utility, as prognostic biomarkers in ovarian cancer, based on the intrinsic link with cancer-associated inflammatory mediators. Based on the data from the specialized literature, the conclusion is that in ovarian cancer, the inflammatory process induced by the presence of the tumor, induces changes in the types of circulating leukocytes, with immediate effects on the markers of systemic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania.
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Faculty of Midwifery and Nursing, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Cantacuzino National Medico-Military Institute for Research and Development, Bucharest, Romania.
- Romanian Academy of Medical Sciences.
- Faculty of General Nursing, Bioterra University, Bucharest, Romania.
ORCID-Profile: Bogdan-Ioan Coculescu
Zitieren
APA
Dinca, A. L., Diaconu, A., Birla, R. D., Coculescu, B. I., Dinca, V. G., Manole, G., Marica, C., Tudorache, I. S., Panaitescu, E., Constantinoiu, S. M., & Coculescu, E. C. (2023). Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators—a review. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231178769
Vancouver
Dinca AL, Diaconu A, Birla RD, Coculescu BI, Dinca VG, Manole G, et al. Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators—a review. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231178769
BibTeX
@article{Dinca2023,
author = {Dinca, Alexandra-Ligia and Diaconu, Adriana and Birla, Rodica Daniela and Coculescu, Bogdan-Ioan and Dinca, Valeriu-Gabi and Manole, Gheorghe and Marica, Cristian and Tudorache, Ioan Sorin and Panaitescu, Eugenia and Constantinoiu, Silviu Marian and Coculescu, Elena Claudia},
title = {Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators—a review},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2023},
doi = {10.1177/03946320231178769}
}
EUVIMED